These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33917026)

  • 21. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
    Turner BC; Eves T; Refaeli Y
    DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
    Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BH3 mimetics: status of the field and new developments.
    Billard C
    Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737.
    Štefaniková A; Klačanová K; Pilchová I; Hatok J; Račay P
    Gen Physiol Biophys; 2017 Dec; 36(5):539-547. PubMed ID: 29372687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
    Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts.
    Nocquet L; Roul J; Lefebvre CC; Duarte L; Campone M; Juin PP; Souazé F
    Sci Rep; 2024 Jun; 14(1):14177. PubMed ID: 38898061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
    Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
    Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bcl-2 family inhibitors sensitize human cancer models to therapy.
    Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
    Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
    Jullien M; Gomez-Bougie P; Chiron D; Touzeau C
    Cells; 2020 Mar; 9(3):. PubMed ID: 32183335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics.
    Villalobos-Ortiz M; Ryan J; Mashaka TN; Opferman JT; Letai A
    Cell Death Differ; 2020 Mar; 27(3):999-1007. PubMed ID: 31332296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
    Scarfò L; Ghia P
    Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes.
    Pemberton JM; Nguyen D; Osterlund EJ; Schormann W; Pogmore JP; Hirmiz N; Leber B; Andrews DW
    Elife; 2023 Apr; 12():. PubMed ID: 37078707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.
    Seyfried F; Stirnweiß FU; Niedermayer A; Enzenmüller S; Hörl RL; Münch V; Köhrer S; Debatin KM; Meyer LH
    Leukemia; 2022 Apr; 36(4):901-912. PubMed ID: 35031695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.
    Pécot J; Maillet L; Le Pen J; Vuillier C; Trécesson SC; Fétiveau A; Sarosiek KA; Bock FJ; Braun F; Letai A; Tait SWG; Gautier F; Juin PP
    Cell Rep; 2016 Dec; 17(12):3347-3358. PubMed ID: 28009301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide.
    Hadji A; Schmitt GK; Schnorenberg MR; Roach L; Hickey CM; Leak LB; Tirrell MV; LaBelle JL
    Oncotarget; 2019 Oct; 10(58):6219-6233. PubMed ID: 31692812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.